SPDR S&P Pharmaceuticals ETF (XPH)
| Assets | $156.31M |
| Expense Ratio | 0.35% |
| PE Ratio | 15.63 |
| Shares Out | 3.60M |
| Dividend (ttm) | $0.70 |
| Dividend Yield | 1.61% |
| Ex-Dividend Date | Sep 23, 2024 |
| Payout Ratio | 25.13% |
| 1-Year Return | +7.16% |
| Volume | 58,355 |
| Open | 43.19 |
| Previous Close | 43.25 |
| Day's Range | 43.07 - 43.95 |
| 52-Week Low | 38.88 |
| 52-Week High | 48.76 |
| Beta | 0.72 |
| Holdings | 44 |
| Inception Date | Jun 19, 2006 |
About XPH
Fund Home PageThe SPDR S&P Pharmaceuticals ETF (XPH) is an exchange-traded fund that is based on the S&P Pharmaceuticals Select Industry index. The fund tracks an equal-weighted index of US pharmaceutical companies. XPH was launched on Jun 19, 2006 and is issued by State Street.
Top 10 Holdings
41.76% of assets| Name | Symbol | Weight |
|---|---|---|
| Corcept Therapeutics Incorporated | CORT | 5.40% |
| Bristol-Myers Squibb Company | BMY | 4.61% |
| Jazz Pharmaceuticals plc | JAZZ | 4.54% |
| Intra-Cellular Therapies, Inc. | ITCI | 4.49% |
| Viatris Inc. | VTRS | 4.19% |
| Axsome Therapeutics, Inc. | AXSM | 3.86% |
| Edgewise Therapeutics, Inc. | EWTX | 3.74% |
| Perrigo Company plc | PRGO | 3.73% |
| Tarsus Pharmaceuticals, Inc. | TARS | 3.65% |
| Pfizer Inc. | PFE | 3.54% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2024 | $0.195 | Sep 25, 2024 |
| Jun 24, 2024 | $0.156 | Jun 26, 2024 |
| Mar 18, 2024 | $0.173 | Mar 21, 2024 |
| Dec 18, 2023 | $0.174 | Dec 21, 2023 |
| Sep 18, 2023 | $0.120 | Sep 21, 2023 |
| Jun 20, 2023 | $0.124 | Jun 23, 2023 |
News
XPH: A More Balanced Way To Get Exposure To Pharmaceuticals
The SPDR S&P Pharmaceuticals ETF offers broad-based exposure to the U.S. pharmaceuticals sector, making it a good option for investing in the industry. XPH tracks the performance of the S&P Pharmaceut...
XPH: Non-Diversified U.S.-Based Large-Cap Pharma ETF Isn't Very Attractive
XPH's consistent low yield and poor price growth (mostly negative) over both short-run as well as over long-run should be disheartening for investors. Expiration of a large number of patents within 20...
XPH: Revenue Challenges Ahead For U.S. Pharmaceuticals
XPH gives you exposure to a broad-based cut of the US Pharmaceuticals sector. Patent expirations are a major headwind affecting many companies in the industry.
Will 2023 be the year that pharma M&A makes a comeback?
A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies, though none has generated the kind of excitement seen in years past.
XPH: U.S. Pharmaceuticals Stocks Are Probably Fairly Valued, Cyclically Unattractive
XPH invests in U.S. pharmaceuticals stocks. The fund is concentrated in 44 holdings.
Final Trades: Pharma, Chevron, Uber & more
The "Halftime Report" traders give their top picks to watch for the second half.
What The Inflation Reduction Act Means For Drug Prices
The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs ...
Get ready for more merger mania in pharma sector the rest of the year
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Pharma market investments: How ETFs help you dabble in the sector at a modest price
Some health care sector ETFs have exposure to companies like Johnson & Johnson, Pfizer, UnitedHealth
Dark Clouds On The Horizon For Big Pharma
According to the most recent healthcare report from the OECD, prescribed medicines here in the United States cost $1025.60 per capita, where the average per capita spending in the developed countries ...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
3 Pharmaceutical ETFs That Could Be Due For A Rebound
These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. Support is a large concentration of buyers who have gathered around the same price level.
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
Healthcare: A Wide Choice Of Large And Well-Established Companies
The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets...
Best Pharmaceutical ETFs for Q1 2021
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.
Pharma Stocks Poised to Move Higher
Nearby support on the charts suggests that the pharmaceuticals sector could be one to watch over the last few months of 2020.
President Trump signs executive orders aimed at lowering drug prices
CNBC's Meg Tirrell reports President Trump has signed four executive orders aimed at lowering drug prices. They include the U.S. allowing importation of prescription drugs from Canada and other countr...
Trump announces series of executive orders aimed at lowering drug costs
President Donald Trump on Friday signed four executive orders aimed at lowering the high cost of prescription drugs in the United States in what would make sweeping changes to the prescription drug ma...
Where this top-rated financial advisor is finding opportunities in the market now
Hightower Treasury Partners CIO Richard Saperstein outlines the areas of the market where he currently sees opportunity.
What does the investment committee recommend in health care? #AskHalftime
The "Halftime Report" traders answer viewer questions in #AskHalftime.
Mizuho: Smaller companies are leading the way in developing vaccines for infectious diseases
Mara Goldstein of Mizuho discusses the difficulty of developing a vaccine quickly during a virus outbreak, and which large and smaller biotech and drug companies investors should be focused on.
